2020 Nelson's Pediatric Antimicrobial Therapy
Autor John S. Bradley, John D. Nelson, Elizabeth Barnetten Limba Engleză Paperback – 15 ian 2020
Drug descriptions cover pediatric-appropriate antimicrobial agents available today and include complete information about dosing regimens.
New in the 26th edition:
- First pediatric approval of beta-lactam/beta-lactamase inhibitor for CRE (carbapenem-resistant enteric bacilli), ceftazidime-avibactam
- Replacement antibiotics for cefotaxime (lack of availability in the US), including ceftriaxone and cefepime (for neonates)
- Situations in which ceftaroline is preferred over vancomycin by the Editors for MRSA infections
- Updates on management of influenza, including baloxavir (now approved for children >12 years)
- New approaches to treatment of mucomycosis
- New recommendations for malaria
- More than 150 new references
Preț: 301.05 lei
Preț vechi: 316.89 lei
-5%
Puncte Express: 452
Preț estimativ în valută:
57.68€ • 62.62$ • 49.46£
57.68€ • 62.62$ • 49.46£
Carte nepublicată încă
Doresc să fiu notificat când acest titlu va fi disponibil:
Se trimite...
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781610023528
ISBN-10: 1610023528
Pagini: 320
Dimensiuni: 123 x 174 x 22 mm
Greutate: 0.27 kg
Ediția:00026
Editura: AMER ACADEMY OF PEDIATRIC
ISBN-10: 1610023528
Pagini: 320
Dimensiuni: 123 x 174 x 22 mm
Greutate: 0.27 kg
Ediția:00026
Editura: AMER ACADEMY OF PEDIATRIC
Descriere
The 26th edition provides practical, evidence-based recommendations from the experts in antimicrobial therapy for treatment of infectious diseases in children. For each disease, the authors provide a commentary to help health care providers select the best of all antimicrobial choices.
Drug descriptions cover pediatric-appropriate antimicrobial agents available today and include complete information about dosing regimens.
New in the 26th edition:
- First pediatric approval of beta-lactam/beta-lactamase inhibitor for CRE (carbapenem-resistant enteric bacilli), ceftazidime-avibactam
- Replacement antibiotics for cefotaxime (lack of availability in the US), including ceftriaxone and cefepime (for neonates)
- Situations in which ceftaroline is preferred over vancomycin by the Editors for MRSA infections
- Updates on management of influenza, including baloxavir (now approved for children >12 years)
- New approaches to treatment of mucomycosis
- New recommendations for malaria
- More than 150 new references